Search the site
Warren Sprigings
Partner
Warren’s practice has focused on litigation in the pharmaceutical industry including Patented Medicines (Notice of Compliance) proceedings, patent infringement / validity proceedings, trademark actions and oppositions and damage quantifications. Warren is a registered Canadian Patent and Trademark Agent, as well as a registered U.S. Patent Agent. His experience includes drafting and prosecuting patent and trademark applications.
Education
- B.A.Sc., University of Ottawa
- LL.B., University of Ottawa
Bar Admission
- Ontario, 1992
Recognition
- "Terrific litigator who shines in pharmaceutical patent disputes." – WWL, 2021
My recent cases
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,496,249 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,738,367 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,696,558 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,782,179 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,472,399, 2,590,511 and 2,703,598 (sacubitril/valsartan)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,732,803 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,649,922 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,936,852, 2,485,143, 2,544,621 and 2,781,799 (riociguat)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,752,437 (linagliptin).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,845,553 (tenofovir alafenamide).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,845,553 and 2,990,210 (tenofovir alafenamide/emtricitabine).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,440,472, 2,521,885, and 2,803,922 (doxycycline)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent Nos. 2,621,273 and 2,659,770 (macitentan)
Action under the new Patented Medicines (Notice of Compliance) Regulations relating to Patent No. 2,402,894 (saxagliptin)
Application for leave to appeal to the Supreme Court of Canada in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone)
Interlocutory appeal in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)
Motion/Application under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab)
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), TMA157,162 (ENERGIZER) and TMA740,338 (ENERGIZER)
Statutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)
Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,415,403 (acetaminophen)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,705,733 (acetaminophen)
Patent infringement case regarding Patent No. 2,407,556 (trastuzumab)
Patent impeachment case regarding Patent No. 2,540,547 (trastuzumab)
Patent impeachment case regarding Patent No. 2,329,829 (trastuzumab)
Patent impeachment case regarding Patent No. 2,376,596 (trastuzumab)
Patent infringement case regarding Patent No. 2,787,952 (bevacizumab) with counterclaim for infringement under the new Patented Medicines (Notice of Compliance) Regulations
Patent impeachment case regarding Patent No. 2,596,133 (trastuzumab)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,366,785 and 2,476,934 (etanercept)
Appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Action under the Trademarks Act and the Competition Act regarding Registration Nos. TMA580,557 (ENERGIZER MAX), 157,162 (ENERGIZER) and 740,338 (ENERGIZER)
Interlocutory appeal in a patent impeachment case regarding Patent No. 2,261,630 (infliximab)
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,261,630 (infliximab).
Application under the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,166,483, 2,186,037, 1,338,377, 2,133762, 2,170,647, 2,290,963, 2,346,988, 2,166,794, 2,139,653, 2,180,535, 2,290,531, 2,226,184 and 2,193,994 (esomeprazole)
Trademark infringement case regarding Registration No. TMA396,079 (FREEDOMWALKER)
Trademark infringement case regarding Registration No. TMA396,079 (FREEDOMWALKER)
Application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 1,340,794 and 2,031,890 (pemetrexed).
Action under section 8 of the old Patented Medicines (Notice of Compliance) Regulations regarding patent No. 2,327,285, 2,325,045, 2,297,163 and 2,134,674 (pregabalin).
Judicial review application regarding Patent No. 2,261,630 (infliximab)
Patent impeachement and patent infringement case regarding Patent No. 2,261,630 (infliximab).
Patent infringement case regarding Patent No. 1,336,777 (clopidogrel).
Patent infringement case regarding Patent No. 1,336,777 (clopidogrel).
Appeal in a patent infringement case regarding Patent No. 1,340,083 (valacyclovir).
Appeal in a patent infringement case regarding Patent No. 1,340,083 (valacyclovir).
Appeal of an application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,372,576 and 2,219,475 (fenofibrate)
Appeal of an application under subsection 6(1) the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,372,576 and 2,219,475 (fenofibrate)
Appeal of an application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,487,054 (fenofibrate)
Appeal of an application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,487,054 (fenofibrate)
Appeal of an application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,487,054 (fenofibrate)
Action under to section 8 of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,173,457 (finasteride)
Action under to section 8 of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,267,136 and 2,325,014 (desloratadine)
Action pursuant to section 8 of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 1,340,083 (valacyclovir)
Application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,219,475 (fenofibrate)
Application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,372,576 and 2,219,475 (fenofibrate)
Action under section 8 of the old Patented Medicines (Notice of Compliance) Regulations regarding multiple patents (atorvastatin)
Application under subsection 6(1) of the old Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,487,054 (fenofibrate)
More people
.jpg)
.jpg)
.jpg)
%20(1).jpg)
